Previous 10 | Next 10 |
- Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis - - Partnering momentum continues into 2023 with $175 million payment associated with ...
2023-03-06 11:15:58 ET Voyager Therapeutics ( NASDAQ: VYGR ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, before market open. The consensus EPS Estimate is -$0.50 (-433.3% Y/Y) and the consensus Revenue Estimate is $3.73M (-86.7% Y/Y). Over the l...
2023-03-06 10:17:11 ET Major earning expected before the bell on Tuesday include: Canaan ( CAN ) DICK'S Sporting Goods ( DKS ) Sea ( SE ) Alaunos Therapeutics ( TCRT ) Thor Industries ( THO ) For further details see: Notable earnings befor...
Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement to include capsids for up to two additional targets extends for next 18 months CAM...
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report fourth quarter and full year 2023 financial and operating results before the m...
Summary Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February. The FDA accepted Neurocrine Biosciences' sNDA for valbenazine as a treatm...
Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence . Fortunately, the biotech's shares aren't falling in response t...
Summary In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle some of the most difficult to treat neurological conditions like Alzheimer's disease, ALS, and Parkinson's. The recent Neuro...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com Apexigen (NASDAQ: APGN ) stock is rocketing higher on Monday following new coverage of the company from an analyst. EF Hutton Acquisition Co. is behind this with its coverage o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roman Tiraspolsky / Shutterstock.com Party City (NYSE: PRTY ) stock is in the news Monday as investors prepare for the retail company to file for bankruptcy. While there’s no official filing just ye...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...